Search Result

Herpes zoster (HZ) results from reactivation of a latent varicella zoster virus (VZV) infection. Clinical manifestations are more common and possibly severe in immunodepressed patients, such as cancer patients. Indeed, HZ can even lead to life-threatening complications. We report the case of an atypical presentation of HZ in an advanced urothelial cancer patient, presenting with long prodromal symptoms and late vesicular eruption. Given the atypical presentation of HZ reactivation among some immunocompromised patients, this case emphasizes the need of clinical suspicion for HZ as differential diagnosis. Furthermore, clinician awareness of prevention of HZ with the recombinant zoster vaccine (RZV) in immunodepressed individuals is also critical to minimize the risk of disease activation and associated morbidity in such patients.

The immune response against human immunodeficiency virus (HIV) infection is a complex interplay between various components of the immune system, with CD8+ T-cells occupying a central role in viral control. This review critically examines the functionality of CD8+ T-cells in HIV defense, highlighting their importance in controlling viral replication, the evasion strategies employed by HIV, and the challenges encountered in harnessing CD8-mediated immunity for therapeutic purposes. We discuss the heterogeneity of CD8+ T-cell responses, the mechanisms of viral escape, and the phenomenon of CD8+ T-cell exhaustion. Additionally, recent advancements and controversies in the field are addressed, along with future perspectives on enhancing CD8-mediated immunity as a therapeutic strategy against HIV. This review aims to provide a comprehensive understanding of the complexities surrounding CD8+ T-cell functionality in HIV defense, paving the way for further research and therapeutic developments in the fight against HIV/AIDS.

The chemotherapy of cancer disease become increasingly important in recent years because ease of operation. The traditional cancer chemotherapy is based on the promise that tumor cells are more likely to be killed by anticancer drugs because of the faster proliferation of those cancer cells. However, in reality most of the drugs cannot differentiate cancer cells from the normal cells. This result the undesirable effect of the drug because of the lack of selectivity i.e the patients always at risk of cytotoxicity. So the development of tumor targeted drug delivery systems in which they recognize the intrinsic difference between normal cells and tumor cells is an important requirement for effective tumor therapy. These carriers include nanoparticles, nanotubes, Nano rods, centromeres, micelles, solid lipid nanoparticles, microspheres. (1) In this experiment, all the materials used in the experiments were of analytical grade. Synthesis of CDI-activated poloxamer-407, NH2 terminated poloxamer-407, Folate conjugated poloxamer-407 and prototype formulation of Liquid crystalline nanoparticle were prepared. Drug loading was done with the optimized formula. In vitro drug release from the nanoparticles was determined in phosphate buffer pH 7.4 and Zero-order model, first order model, Higuchi’s model, kosmeyer-Peppas model also tried for compatibility. The cytotoxicity studies in the final formula by Brine shrimp experiments were done and found that it is significant. There are only 0.01% differences in each case. It was found that in-vitro drug release of resveratrol from optimized LCN at pH 7.4 and pH5 was best explained by Higuchi’s equation, as the plot showed the highest linearity with a regression coefficient of 0.9528 and 0.9404 respectively. The entrapment efficiency of optimized LCN was found to be 87.43 ± 0.52 % which was in close agreement with the value predicted by design expert software. It was found that the invitro drug release of resveratrol from optimized LCN at pH 7.4 and pH 5 was best explained by Higuchi’s equation, as the plot showed the highest linearity with a regression coefficient of 0.9528 and 0.9404 respectively.